ARGX 111

Next Previous
Drug Profile

ARGX 111

Alternative Names: Anti-cMet SIMPLE Antibody; ARGX-111

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator arGEN-X
  • Developer argenx
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in Belgium (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in France (Parenteral)
  • 24 Aug 2017 argenx has patent protection for ARGX 111 in Japan and European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top